Reversal of ABCB1-related multidrug resistance by ERK5-IN-1
نویسندگان
چکیده
منابع مشابه
Reversal of Multidrug Resistance by Lipophilic Drugs1
The phenomenon of multidrug resistance implies that a wide spectrum of structurally and functionally unrelated chemotherapeutic drugs are recognized and processed by the molecular system which protects multidrug-resistant (MDR) cells against lipophilic cytotoxic drugs. This suggests that lipophilic agents with low toxicity may also be recognized and processed by this molecular system. At high c...
متن کاملReversal of multidrug resistance by RU 486.
P-Glycoproteins represent a family of drug efflux proteins that convey multidrug resistance to cells in which they are expressed. This phenomenon can lower the efficacy of drugs used in chemotherapy. The steroid progesterone has been shown to bind P-glycoproteins and inhibit their drug efflux. We report that the antiprogestin RU 486 can reverse multidrug resistance in cells overexpressing the m...
متن کاملReversal of Multidrug Resistance by RU 4861
P-Glycoprotelns represent a family of drug efflux proteins that convey multidrug resistance to cells In which they are expressed. This phenome non can lower the efficacy of drugs used in chemotherapy. The steroid progesterone has been shown to bind P-glycoproteins and inhibit their drug emux. We report that the antiprogestin RU 486 can reverse multi drug resistance In cells overexpressing the m...
متن کاملTrametinib modulates cancer multidrug resistance by targeting ABCB1 transporter
Overexpression of adenine triphosphate (ATP)-binding cassette (ABC) transporters is one of the main reasons of multidrug resistance (MDR) in cancer cells. Trametinib, a novel specific small-molecule mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor, is currently used for the treatment of melanoma in clinic. In this study, we investigated the effect of trametinib on MDR med...
متن کاملClinical Reversal of Multidrug Resistance.
Reversal of drug resistance offers the hope of increasing the efficacy of conventional chemotherapy. We tested dexverapamil as a P-glycoprotein antagonist in combination with EPOCH chemotherapy in refractory non-Hodgkin's lymphoma. In a cross-over design, dexverapamil was added to EPOCH after disease stabilization or progression occurred. Objective responses were observed in 10 of 41 assessable...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Experimental & Clinical Cancer Research
سال: 2020
ISSN: 1756-9966
DOI: 10.1186/s13046-020-1537-9